Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease

BACKGROUND AND AIM: Adalimumab is administered and dosed using a standardized treatment regimen. Although therapeutic drug monitoring (TDM) may help optimize treatment efficacy, the lower cut‐off concentration of adalimumab needed to retain disease remission has not been established. This cross‐sect...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JGH Open
Prif Awduron: Carlsen, Arne, Omdal, Roald, Karlsen, Lars, Kvaløy, Jan Terje, Aabakken, Lars, Steinsbø, Øyvind, Bolstad, Nils, Warren, David, Lundin, Knut Erik Aslaksen, Grimstad, Tore
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wiley Publishing Asia Pty Ltd 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7273736/
https://ncbi.nlm.nih.gov/pubmed/32514446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12266
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg